Quarterly Report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTER ENDED MAY 31, 2009

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______to _______

Commission File Number

1-604

WALGREEN CO.

(Exact name of registrant as specified in its charter)

Illinois	36-1924025
(State of Incorporation)	(I.R.S. Employer Identification No.)

200 Wilmot Road, Deerfield, Illinois	60015
(Address of principal executive offices)	(Zip Code)

(847) 914-2500

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer”, “accelerated filer" and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer þ Accelerated Filer ¨

Non-accelerated filer ¨ (Do not check if a smaller reporting company) Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No þ

The number of shares outstanding of the registrant's Common Stock, $.078125 par value, as of May 31, 2009 was 992,380,086.

WALGREEN CO.

FORM 10-Q FOR THE QUARTER ENDED MAY 31, 2009

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1.	Consolidated Condensed Financial Statements (Unaudited)
	a)	Balance Sheets
	b)	Statements of Earnings
	c)	Statements of Cash Flows
	d)	Notes to Financial Statements
Item 2.	Management’s Discussion and Analysis of Results of Operations and Financial Condition
Item 3.	Qualitative and Quantitative Disclosure about Market Risk
Item 4.	Controls and Procedures

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds
Item 6.	Exhibits

PART 1. FINANCIAL INFORMATION

Item 1.

WALGREEN CO. AND SUBSIDIARIES CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

The consolidated condensed financial statements included herein have been prepared by the company pursuant to the rules and regulations of the Securities and Exchange Commission. The Consolidated Condensed Balance Sheets as of May 31, 2009, August 31, 2008 and May 31, 2008, the Consolidated Condensed Statements of Earnings for the three and nine months ended May 31, 2009 and 2008, and the Consolidated Condensed Statements of Cash Flows for the nine months ended May 31, 2009 and 2008, have been prepared without audit. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the company believes that the disclosures are adequate to make the information presented not misleading. It is suggested that these consolidated condensed financial statements be read in conjunction with the financial statements and the notes thereto included in the company's latest annual report on Form 10-K.

In the opinion of the company, the consolidated condensed statements for the unaudited interim periods presented include all adjustments, consisting of normal recurring adjustments, necessary to present a fair statement of the results for such interim periods. Because of the influence of certain holidays, seasonal and other factors on the company's operations, net earnings for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of earnings for the full year.

WALGREEN CO. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
(UNAUDITED)
(In millions, except per share amounts)

	May 31,			August 31,			May 31,
	2009			2008			2008
Assets
Current Assets:
Cash and cash equivalents	$	2,300		$	443		$	472
Short term investments		100			-			-
Accounts receivable, net		2,797			2,527			2,395
Inventories		6,891			7,249			7,064
Other current assets		164			214			253
Total Current Assets		12,252			10,433			10,184

Non-Current Assets:
Property and equipment, at cost, less accumulated depreciation and amortization		10,595			9,775			9,311
Goodwill		1,463			1,438			1,418
Other non-current assets		833			764			675
Total Non-Current Assets		12,891			11,977			11,404
Total Assets	$	25,143		$	22,410		$	21,588

Liabilities & Shareholders' Equity
Current Liabilities:
Short-term borrowings	$	10		$	83		$	1,145
Trade accounts payable		4,599			4,289			4,173
Accrued expenses and other liabilities		2,312			2,272			2,161
Income taxes		52			-			23
Total Current Liabilities		6,973			6,644			7,502

Non-Current Liabilities:
Long-term debt		2,338			1,337			19
Deferred income taxes		316			150			150
Other non-current liabilities		1,329			1,410			1,382
Total Non-Current Liabilities		3,983			2,897			1,551

Shareholders' Equity:
Preferred stock $.0625 par value; authorized 32 million shares, none issued		-			-			-
Common stock $.078125 par value; authorized 3.2 billion shares; issued 1,025,400,000 at May 31, 2009, August 31, 2008 and May 31, 2008		80			80			80
Paid-in capital		591			575			573
Employee stock loan receivable		(155	)		(36	)		(44	)
Retained earnings		15,027			13,792			13,460
Accumulated other comprehensive income (loss)		59			9			(4	)
Treasury stock, at cost; 33,019,914 shares at May 31, 2009, 36,223,782 at August 31, 2008 and 35,516,560 at May 31, 2008		(1,415	)		(1,551	)		(1,530	)
Total Shareholders' Equity		14,187			12,869			12,535
Total Liabilities & Shareholders' Equity	$	25,143		$	22,410		$	21,588

The accompanying Notes to Consolidated Condensed Financial

Statements are an integral part of these Statements.

WALGREEN CO. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
(UNAUDITED)
(In millions, except per share amounts)

	Three Months Ended May 31,				Nine Months Ended May 31,
	2009		2008		2009		2008

Net sales	$	16,210	$	15,015	$	47,632	$	44,437
Cost of sales		11,751		10,770		34,365		31,829
Gross Profit		4,459		4,245		13,267		12,608

Selling, general and administrative expenses		3,613		3,331		10,722		9,878
Operating Income		846		914		2,545		2,730

Interest expense, net		25		2		60		4

Earnings Before Income Tax Provision		821		912		2,485		2,726
Income tax provision		299		340		915		1,012
Net Earnings	$	522	$	572	$	1,570	$	1,714

Net earnings per common share – basic	$	.53	$	.58	$	1.59	$	1.73
Net earnings per common share – diluted	$	.53	$	.58	$	1.58	$	1.72

Dividends declared	$	.1125	$	.0950	$	.3375	$	.2850

Average shares outstanding		992.0		990.2		989.6		990.9
Dilutive effect of stock options		1.0		3.8		1.4		5.2
Average shares outstanding assuming dilution		993.0		994.0		991.0		996.1

The accompanying Notes to Consolidated Condensed Financial

Statements are an integral part of these Statements.

WALGREEN CO. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In millions)

	Nine Months Ended May 31,
	2009			2008

Cash Flows from Operating Activities :
Net earnings	$	1,570		$	1,714
Adjustments to reconcile net earnings to net cash provided by operating activities -
Depreciation and amortization		741			608
Deferred income taxes		253			(59	)
Stock compensation expense		67			56
Income tax savings from employee stock plans		-			1
Other		9			7
Changes in operating assets and liabilities -
Accounts receivable, net		(298	)		(273	)
Inventories		426			(233	)
Other assets		-			(20	)
Trade accounts payable		303			430
Accrued expenses and other liabilities		55			43
Income taxes		116			167
Other non-current liabilities		17			50
Net cash provided by operating activities		3,259			2,491

Cash Flows from Investing Activities :
Purchases of short-term investments held to maturity		(1,400	)		-
Proceeds from sale of short-term investments held to maturity		1,300			-
Additions to property and equipment		(1,534	)		(1,653	)
Proceeds from sale of assets		35			14
Business and intangible asset acquisitions, net of cash received		(348	)		(527	)
Net proceeds from corporate-owned life insurance policies		11			12
Net cash used for investing activities		(1,936	)		(2,154	)

Cash Flows from Financing Activities :
Net (payments) proceeds from short-term borrowings		(70	)		263
Net proceeds from issuance of long-term debt		987			-
Payments of debt		-			(29	)
Stock purchases		(140	)		(220	)
Proceeds related to employee stock plans		106			161
Cash dividends paid		(334	)		(283	)
Other		(15	)		(12	)
Net cash provided by (used for) financing activities		534			(120	)

Changes in Cash and Cash Equivalents :
Net increase in cash and cash equivalents		1,857			217
Cash and cash equivalents at September 1		443			255
Cash and cash equivalents at May 31	$	2,300		$	472

The accompanying Notes to Consolidated Condensed Financial

Statements are an integral part of these Statements.

WALGREEN CO. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(1) The consolidated condensed financial statements include the accounts of the company and its subsidiaries. All intercompany transactions have been eliminated. The consolidated condensed financial statements are prepared in accordance with accounting principles generally accepted in the United States of America and include amounts based on management’s prudent judgments and estimates. Actual results may differ from these estimates. For a complete discussion of all our significant accounting policies please see our 2008 annual report on Form 10-K.

The May 31, 2008 balance sheet reflects the reclassification of debt, which was previously condensed within the accrued expenses and other liabilities line and other non-current liabilities line. In addition, software development costs were reclassified from other non-current assets to property and equipment.

(2) On October 30, 2008 we announced a series of strategic initiatives, approved by the Board of Directors, to enhance shareholder value. One of these initiatives was a program designed to reduce cost and improve productivity through strategic sourcing of indirect spend, reducing corporate overhead and work throughout our stores, rationalization of inventory categories, realignment of pharmacy operations and transforming the community pharmacy.

As of May 31, 2009 we have recorded the following pre-tax charges associated with our restructuring initiatives within the Consolidated Statement of Earnings:

	Three Months Ended		Nine Months Ended
	May 31, 2009		May 31, 2009
Severance and other benefits	$	6	$	65
Project cancellation settlements		8		8
Inventory charges		33		44
Restructuring expense		47		117
Consulting and other		20		57
Restructuring and restructuring related costs	$	67	$	174

Cost of sales	$	33	$	44
Selling, general and administrative expense		34		130
	$	67	$	174

The $65 million of severance and other benefits includes the charges associated with 438 employees who participated in the voluntary separation program and 362 employees who were involuntarily separated from the company.

Inventory charges consist of on-hand inventory that has been reduced from cost to current selling prices and the loss we incurred on the sale of inventory below cost.

As of May 31, 2009 we have recorded the following balances within the accrued expenses and other liabilities section of our Consolidated Balance Sheets:

		August 31, 2008 Reserve Balance				Charges				Cash Payments				May 31, 2009 Reserve Balance
Severance and other benefits		$	-			$	72			$	61			$	11

(3) Short-term investments at May 31, 2009 include a $100 million Treasury Bill maturing in October 2009. The interest rate on the Treasury Bill is less than one percent. The investment is held to maturity and recorded at cost in accordance with SFAS 115 Accounting for Certain Investments in Debt and Equity Securities. The fair value of the Treasury Bill at May 31, 2009 approximated cost.

(4) Inventories are valued on a lower of last-in, first-out (LIFO) cost or market basis. At May 31, 2009, August 31, 2008 and May 31, 2008, inventories would have been greater by $1,191 million, $1,067 million and $1,042 million respectively, if they had been valued on a lower of first-in, first-out (FIFO) cost or market basis. LIFO inventory costs can only be determined annually when inflation rates and inventory levels are finalized; therefore, LIFO inventory costs for interim financial statements are estimated. Inventory includes product cost, inbound freight, warehousing costs and vendor allowances not included as a reduction of advertising expense.

(5) The principal retirement plan for employees is the Walgreen Profit-Sharing Retirement Trust to which both the company and participating employees contribute. The company's contribution, which is determined annually at the discretion of the Board of Directors, has historically related to pre-tax income; however, beginning January 1, 2008, a portion of that contribution is in the form of a guaranteed match. The profit-sharing provision was $73 million for the current quarter and $221 million for the nine month period compared to $81 million and $242 million in the same periods last year. The company’s contributions, which are made annually in the second quarter, were $301 million for the nine month period ended May 31, 2009. This compares to $261 million for the prior year.

(6) The company granted 234,716 and 16,906,061 stock options under the Walgreen Co. Executive Stock Option Plan and the Walgreen Co. Stock Purchase/Option Plan (Share Walgreens) for the quarter and nine month period ended May 31, 2009. This compares to 99,917 and 4,255,915 stock options granted in the quarter and nine month period ended under the plans last year. Total stock-based compensation expense was $19 million for the quarter and $68 million for the nine month period ended May 31, 2009 compared to $11 million and $56 million for the comparable periods last year. In accordance with Statement of Financial Accounting Standards (SFAS) No. 123(R), compensation expense is recognized on a straight-line basis over the employee's vesting period or to the employee's retirement eligible date, if earlier. There was $1 million of fully recognized retiree eligible expense recorded in the current quarter and $15 million recorded for the first nine months. This compares to no fully recognized retiree eligible expenses and $16 million for the quarter and nine months ended May 31, 2008. Therefore, compensation expense for the quarter and nine month periods is not representative of compensation expense for the entire fiscal year. There has been no material change in the assumptions used to compute compensation expense during the current quarter or year.

The company granted 15,423 and 514,470 restricted stock units under the new Walgreen Co. Restricted Stock Unit Award Program and 17,443 and 546,096 performance shares under the new Walgreen Co. Performance Share Program for the quarter and nine months ended May 31, 2009. In accordance with SFAS No. 123(R), compensation expense is recognized on a straight line basis based on a three year cliff vesting schedule for the Restricted Stock Unit Award Program and straight line over a three year vesting schedule for the Performance Share Program. For the quarter and nine month periods ended May 31, 2009 the company recognized $3 million and $10 million of expense related to these new plans, respectively.

(7) The company provides certain health insurance benefits for retired employees who meet eligibility requirements, including age, years of service and date of hire. The costs of these benefits are accrued over the period earned. The company's postretirement health benefit plans are not funded.

	Three Months Ended						Nine Months Ended
Components of Net Periodic Benefit Costs (In millions)	May 31, 2009			May 31, 2008			May 31, 2009			May 31, 2008
Service cost	$	3		$	4		$	10		$	10
Interest cost		7			6			20			18
Amortization of actuarial loss		1			1			3			4
Amortization of prior service cost		(1	)		(1	)		(3	)		(3	)
Special retirement benefit		-			-			4			-
Curtailment (gain)/loss		(16	)		-			(16	)		-
Total postretirement benefit (income)/cost	$	(6	)	$	10		$	18		$	29

In May 2009, we amended the company’s postretirement health benefit plans to change the eligibility requirements. As a result of this amendment we recognized curtailment income of $16 million for the quarter ended May 31, 2009.

Additionally in the second quarter, the company recognized a special retirement benefit expense of $4 million related to accelerating eligibility for certain employees who elected special early retirement as a part of our initiative to enhance shareholder value.

(8) The company guarantees a credit agreement on behalf of SureScripts-RxHub, LLC, which provides electronic prescription data services. This credit agreement, for which SureScripts-RxHub, LLC is primarily liable, has an expiration date of June 30, 2011. The liability was $10 million at May 31, 2009, $8 million at August 31, 2008 and $7 million at May 31, 2008. The maximum amount of future payments that could be required under the guaranty is $25 million, of which $13 million may be recoverable from another guarantor. In addition, under certain circumstances the company may be required to provide an additional guarantee of up to $10 million, of which $8 million may be recoverable from other guarantors. This guarantee arose as a result of a business decision between parties to ensure that the operations of SureScripts-RxHub, LLC would have additional support to access financing. Should SureScripts-RxHub, LLC default or become unable to pay its debts, the company would be required to fulfill our portion of this guarantee.

(9) The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares for the periods presented. At May 31, 2009 and 2008, outstanding options to purchase common shares of 49,354,716 and 12,998,212, respectively were excluded from the calculation.

(10) Short-term borrowings and long-term debt consists of the following at May 31, 2009 and 2008 (in millions):

	May 31, 2009			May 31, 2008
Short-Term Borrowings -
Commercial paper	$	-		$	1,137
Current maturities of loans assumed through the purchase of land and buildings; various interest rates from 3.50% to 8.75%; various maturities from 2009 to 2035		5			8
Other		5			-
Total short-term borrowings	$	10		$	1,145

Long-Term Debt -
4.875% unsecured notes due 2013 net of unamortized discount	$	1,296		$	-
5.250% unsecured notes due 2019 net of unamortized discount		995			-
Loans assumed through the purchase of land and buildings; various interest rates from 3.50% to 8.75%; various maturities from 2009 to 2035		52			27
		2,343			27
Less current maturities		(5	)		(8	)
Total-long term debt	$	2,338		$	19

In fiscal 2009 and 2008 the company issued commercial paper to support working capital needs. The short-term borrowings under the commercial paper program had the following characteristics (in millions):

	May 31, 2009			May 31, 2008
Balance outstanding at end of period	$	-		$	1,137
Maximum outstanding at any month-end		1,068			1,167
Average daily short-term borrowings		364			743
Weighted-average interest rate		1.97	%		2.21	%

The carrying value of the commercial paper approximates the fair value.

In connection with our commercial paper program, we maintain two unsecured backup syndicated lines of credit that total $1,200 million. The first $600 million facility expires on August 10, 2009; the second expires on August 12, 2012. Our ability to access these facilities is subject to our compliance with the terms and conditions of the credit facilities, including financial covenants. The covenants require us to maintain certain financial ratios related to minimum net worth and priority debt, along with limitations on the sale of assets and purchases of investments. The company pays a facility fee to the financing bank to keep the line of credit facility active. As of May 31, 2009, there have been no borrowings against the credit facilities. On December 9, 2008, we entered into an additional $175 million line of credit that expired on December 31, 2008.

On July 17, 2008, we issued notes totaling $1,300 million bearing an interest rate of 4.875% paid semiannually in arrears on February 1 and August 1 of each year, beginning on February 1, 2009. The notes will mature on August 1, 2013. We may redeem the notes, at any time in whole or from time to time in part, at our option at a redemption price equal to the greater of: (1) 100% of the principal amount of the notes to be redeemed; or (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate, plus 30 basis points, plus accrued interest on the notes to be redeemed to, but excluding, the date of redemption. If a change of control triggering event occurs, unless we have exercised our option to redeem the notes, we will be required to offer to repurchase the notes at a purchase price equal to 101% of the principal amount of the notes plus accrued and unpaid interest to the date of redemption. The notes are unsecured senior debt obligations and rank equally with all other unsecured senior indebtedness of the company. The notes are not convertible or exchangeable. Total issuance costs relating to this offering were $9 million, which included $8 million in underwriting fees. The fair value of the notes as of May 31, 2009, was $1,394 million . Fair value was determined based upon discounted future cash flows for these notes.

On January 13, 2009, we issued notes totaling $1,000 million bearing an interest rate of 5.25% paid semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2009. The notes will mature on January 15, 2019. We may redeem the notes, at any time in whole or from time to time in part, at our option at a redemption price equal to the greater of: (1) 100% of the principal amount of the notes to be redeemed; or (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate, plus 45 basis points, plus accrued interest on the notes to be redeemed to, but excluding, the date of redemption. If a change of control triggering event occurs, unless we have exercised our option to redeem the notes, we will be required to offer to repurchase the notes at a purchase price equal to 101% of the principal amount of the notes plus accrued and unpaid interest to the date of redemption. The notes are unsecured senior debt obligations and rank equally with all other unsecured senior indebtedness of the company. The notes are not convertible or exchangeable. Total issuance costs relating to this offering were $8 million, which included $7 million in underwriting fees. The fair value of the notes as of May 31, 2009, was $1,048 million. Fair value was determined based upon discounted future cash flows for these notes.

(11) During the quarter the company aquired and opened 29 Drug Fair locations in addition to selected other assets (primarily prescription files). The aggregate purchase price of all business acquisitions was $348 million for the nine month period ended May 31, 2009. These acquisitions added $210 million to goodwill and intangible assets. The remaining fair value relates to tangible assets, less liabilities assumed. The allocations of the purchase price for all acquisitions, except Drug Fair, McKesson Specialty and IVPCARE, have been finalized. Operating results of the businesses acquired have been included in the consolidated statements of earnings from their respective acquisition dates forward. Pro forma results of the company, assuming all of the acquisitions had occurred at the beginning of each period presented, would not be materially different from the results reported.

(12) The company is involved in legal proceedings, and is subject to investigations, inspections, audits, inquiries and similar actions by governmental authorities, incidental to the normal course of the company’s business.

In October 2006, a $31 million judgment was entered against the company in Illinois state court. In March 2009, the Illinois Appellate Court reversed the punitive portion of the judgment in the amount of $25 million and the company settled the balance of the claim. Other parties of interest in the matter have appealed the reversal of the punitive damages to the Supreme Court of Illinois.

On April 16, 2008, the Plumbers and Steamfitters Local No. 7 Pension Fund filed a putative class action suit against the company and its former Chief Executive Officer and Chief Operating Officer in the United States District Court for the Northern District of Illinois. The suit was filed on behalf of purchasers of company common stock during the period between June 25, 2007, and November 29, 2007. The complaint, which was amended on October 16, 2008, charges the company and its former Chief Executive Officer and Chief Operating Officer with violations of Section 10(b) of the Securities Exchange Act of 1934, claiming that the company misled investors by failing to disclose declining rates of growth in generic drug sales and a contract dispute with a pharmacy benefits manager that allegedly had a negative impact on earnings. The company and the officers named in the suit believe the allegations are without merit, and intend to defend against them vigorously.

Although the outcome of these and other legal proceedings and investigations to which the company is subject cannot be forecast with certainty, management believes the final disposition of these matters will not have a material adverse effect on the company's consolidated financial position or results of operations.

(13) Cash interest paid for the nine months ended May 31, 2009 was $45 million compared to $11 million in the prior year’s nine month period. Cash paid for income taxes was $523 million and $897 million for the nine months ended May 31, 2009 and May 31, 2008, respectively.

(14) Non-cash transactions in the current fiscal period include $97 million due to the reduction in the liability for postretirement health benefit plans and $19 million in deferred tax assets related to the identification of net operating losses in acquired businesses. There were no material non-cash transactions in the prior year’s period.

(15) We adopted the provisions of SFAS 157, Fair Value Measurements for financial assets and liabilities beginning in the first quarter of fiscal 2009. With the exception of short term investments, we currently do not hold any financial assets or liabilities that are included within the scope of this statement. Our debt instruments are not reported at fair value in our statement of financial position and as a result, we will continue to report under the guidance of SFAS 107, Disclosures about Fair Value of Financial Instruments that requires us to disclose the fair value of our debt in the footnotes. The Financial Accounting Standards Board (FASB) Staff Position No. 157-2 deferred the effective date of nonfinancial assets and liabilities until fiscal year 2010. We do not expect to have a material impact in 2010 when we apply the statement to our nonfinancial assets and liabilities.

(16) Accumulated other comprehensive income at May 31, 2009 was $59 million compared to $9 million in the prior year. In May 2009 the company’s postretirement health benefit plans were amended to change eligibility requirements. As a result of the amendment, our postretirement health benefit plan liability was decreased by $97 million and accumulated other comprehensive income was increased by $50 million net of deferred taxes.

(17) In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interest in Consolidated Financial Statements – an amendment of Accounting Research Bulletin No. 51 . The objective of this statement is to improve the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements by establishing accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. The statement significantly changes the accounting for transactions with minority interest holders. This statement, which will be effective for the first quarter of fiscal 2010, is not expected to have a material impact on our consolidated financial position or results of operations.

In December 2007, the FASB issued SFAS No 141(R), Business Combinations . This statement establishes principles and requirements for how the acquirer recognizes and measures identifiable assets acquired, liabilities assumed and any noncontrolling interest in a business combination. In addition the statement provides a revised definition of a business, shifts from the purchase method to the acquisition method, expenses acquisition-related transaction costs, recognizes contingent consideration and contingent assets and liabilities at fair value, and capitalizes acquired in-process research and development. This statement, which will be effective for the first quarter of fiscal 2010, will be applied prospectively to business combinations. In addition, changes in an acquired entity’s deferred tax assets and uncertain tax positions after the measurement period will impact income tax expense.

In May 2009, the FASB issued SFAS No. 165, Subsequent Events . This statement establishes general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. In particular, this statement sets forth (1) the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements; (2) the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements; and (3) the disclosures that an entity should make about events or transactions that occurred after the balance sheet date. This statement, effective for the fourth quarter in the current fiscal year, will be applied prospectively in future filings.

In June 2009, the FASB approved its Accounting Standards Codification, or Codification, as the single source of authoritative United States accounting and reporting standards applicable for all non-governmental entities, with the exception of the SEC and its staff. The Codification, which changes the referencing of financial standards, is effective for interim or annual financial periods ending after September 15, 2009. Therefore, in the first quarter of fiscal 2010, all references made to US GAAP will use the new Codification numbering system prescribed by the FASB. As the Codification is not intended to change or alter existing US GAAP, it is not expected to have any impact on our consolidated financial position or results of operations.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

INTRODUCTION

Walgreens is principally a retail drugstore chain that sells prescription and non-prescription drugs and general merchandise. General merchandise includes, among other things, beauty care, personal care, household items, candy, photofinishing, greeting cards, convenience foods and seasonal items. Customers can have prescriptions filled in retail pharmacies, as well as through the mail, by telephone and via the Internet. As of May 31, 2009, we operated 7,361 locations in 49 states, the District of Columbia, Guam and Puerto Rico. Total locations do not include 343 convenient care clinics operated by Take Care Health Systems, Inc.

	Number of Locations
Location Type	May 31, 2009		May 31, 2008
Drugstores		6,857		6,252
Worksite Facilities		373		372
Home Care Facilities		112		89
Specialty Pharmacies		17		12
Mail Service Facilities		2		2
Total		7,361		6,727

The drugstore industry is highly competitive. In addition to other drugstore chains, independent drugstores and mail order prescription providers, we also compete with various other retailers including grocery stores, convenience stores, mass merchants and dollar stores.

The long-term outlook for prescription utilization is strong due in part to the aging population and the continued development of innovative drugs that improve quality of life and control health care costs. Certain provisions of the Deficit Reduction Act of 2005 seek to reduce federal spending by altering the Medicaid reimbursement formula for multi-source (i.e., generic) drugs. These changes are expected to result in reduced Medicaid reimbursement rates for prescription drugs. Also, in conjunction with a recently approved class action settlement, the methodology used to calculate the average wholesale price (AWP), a pricing reference widely used in the pharmacy industry, is expected to be reduced for many brand-name prescription drugs effective September 2009. The company expects to reach agreement on adjustments with its third party payors.

We believe deteriorating economic conditions and heightened turmoil in the financial markets have adversely impacted discretionary consumer spending, including spending at retail drugstores. It is unclear the extent to which these conditions will persist and what overall impact they will have on future consumer spending.

Front-end sales have continued to grow primarily due to the addition of new stores. Additionally, front-end sales grew due to strengthening core categories, such as over-the-counter non-prescription drugs, beauty care items, household products and consumables. Walgreens strong name recognition continues to drive private brand sales, which are included in these core categories.

We continue to expand into new markets and increase penetration in existing markets. To support our growth, we are investing in prime locations, technology and customer service initiatives. Retail organic growth continues to be our primary growth vehicle; however, consideration is given to retail and other acquisitions that provide a unique opportunity and strategic fit for our business.

RESTRUCTURING CHARGES

On October 30, 2008 we announced a series of strategic initiatives, approved by the Board of Directors, to enhance shareholder value. One of these initiatives was a program designed to reduce cost and improve productivity through strategic sourcing of indirect spend, reducing corporate overhead and work throughout our stores, rationalization of inventory categories, realignment of pharmacy operations and transforming the community pharmacy. In conjunction with these initiatives approximately $300 to $400 million of costs are anticipated over fiscal 2009 and 2010. We anticipate achieving approximately $1 billion in annual cost savings by fiscal 2011 related to these initiatives.

Additionally, in conjunction with our Customer Centric Retailing (CCR) initiative we are enhancing the store format to ensure we have the proper assortments, better category lay-outs and adjacencies, better shelf height and site lines and better assortment and brand layout, all of which are designed to positively enhance the shopper experience and increase customer frequency and purchase size. This format will be rolled out to approximately 5,000 to 5,500 stores beginning in the fall and continuing through calendar 2010. Although we will continue to refine our estimates as the roll-out progresses, based on our experience with the first thirty-five pilot stores, we expect the cost to be $30 thousand to $50 thousand per store.

As of May 31, 2009 we have recorded the following pre-tax charges associated with our restructuring initiatives within the Consolidated Statement of Earnings:

	Three Months Ended		Nine Months Ended
	May 31, 2009		May 31, 2009
Severance and other benefits	$	6	$	65
Project cancellation settlements		8		8
Inventory charges		33		44
Restructuring expense		47		117
Consulting and other		20		57
Restructuring and restructuring related costs	$	67	$	174

Cost of sales	$	33	$	44
Selling, general and administrative expense		34		130
	$	67	$	174

Inventory reserve charges consist of on-hand inventory that has been reduced from cost to current selling prices and the loss we incurred on the sale of inventory below cost. In addition, as a part of our restructuring efforts we sold an incremental amount of inventory below traditional retail prices. The dilutive effect of these sales on gross profit was $32 million in the current quarter and nine month period.

As of May 31, 2009 we have recorded the following balances within the accrued expenses and other liabilities section of our Consolidated Balance Sheets:

	August 31, 2008 Reserve Balance	Charges	Cash Payments	May 31, 2009 Reserve Balance
Severance and other benefits	$ -	$ 72	$ 61	$ 11

We have realized savings related to these initiatives of approximately $87 million in the current quarter and $139 million for the first nine months. The savings, which are included in selling, general and administrative expense, are primarily the result of reduced store labor and headcount reductions.

OPERATING STATISTICS

	Percentage Changes
	Three Months Ended May 31,					Nine Months Ended May 31,
	2009			2008		2009			2008
Net Sales		8.0			9.6		7.2			10.2
Net Earnings		(8.8	)		2.0		(8.4	)		4.2
Comparable Drugstore Sales		2.8			3.4		1.9			4.5
Prescription Sales		8.2			8.9		7.4			10.3
Comparable Drugstore Prescription Sales		3.8			2.7		3.1			4.5
Front-End Sales		7.4			11.1		6.7			9.9
Comparable Drugstore Front-End Sales		0.9			4.6		(0.2	)		4.4
Gross Profit		5.0			9.5		5.2			9.7
Selling, General and Administrative Expenses		8.4			10.2		8.5			10.5

	Percent to Net Sales
	Three Months Ended May 31,				Nine Months Ended May 31,
	2009		2008		2009		2008
Gross Margin		27.5		28.3		27.9		28.4
Selling, General and Administrative Expenses		22.3		22.2		22.6		22.3

	Other Statistics
	Three Months Ended May 31,				Nine Months Ended May 31,
	2009		2008		2009		2008
Prescription Sales as a % of Net Sales		65.6		65.5		64.9		64.7
Third Party Sales as a % of Total Prescription Sales		95.4		95.5		95.4		95.2
Total Number of Prescriptions (in millions)		168		158		488		466
30 Day Equivalent Prescriptions (in millions) *		187		173		541		510
Total Number of Locations						7,361		6,727

* Includes the adjustment to convert prescriptions greater than 84 days to the equivalent of three 30 day prescriptions. This adjustment reflects the fact these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.

RESULTS OF OPERATIONS

Net earnings for the third quarter ended May 31, 2009 were $522 million or $0.53 per share (diluted). This was an 8.8% decrease over the same quarter last year. Net earnings for the nine months decreased 8.4% to $1,570 million or $1.58 per share (diluted). The net earnings decrease in the quarter and nine months was attributed to a lower rate of sales growth, lower gross margins, higher selling, general and administrative expenses as a percentage of sales and higher interest costs. Additionally, in the current quarter we recorded $47 million in restructuring expenses, $20 million for consulting and other expenses and $32 million in margin dilution related to our restructuring activities. For the nine month period we have recorded $117 million in restructuring expenses, $57 million for consulting and other expenses and $32 million in margin dilution related to our restructuring activities.

Net sales for the third quarter increased by 8.0% to $16,210 million and rose by 7.2% to $47,632 million for the first nine months. Drugstore sales increases resulted from sales gains in existing stores and added sales from new stores, each of which include an indeterminate amount of market-driven price changes. Sales in comparable drugstores were up 2.8% for the quarter and 1.9% for the nine month period. Comparable drugstores are defined as those that have been open for at least twelve consecutive months without closure for seven or more consecutive days and without a major remodel or a natural disaster in the past twelve months. Relocated and acquired stores are not included as comparable stores for the first twelve months after the relocation or acquisition. We operated 7,361 locations as of May 31, 2009, compared to 6,727 a year earlier.

Prescription sales increased by 8.2% for the third quarter and 7.4% for the first nine months and represented 65.6% and 64.9% of total sales, respectively. In the prior year, prescription sales increased 8.9% for the quarter and 10.3% year to date and represented 65.5% and 64.7% of total sales. Comparable drugstore prescription sales were up 3.8% in the current quarter and 3.1% in the nine month period. The effect of generic drugs, which have a lower retail price, replacing brand name drugs reduced prescription sales by 3.8% in the current quarter and 2.8% for the first nine months versus 3.4% in the previous quarter and 4.0% in the previous nine month period. The effect of generics on total sales was a reduction of 2.1% in the current quarter and 1.5% year to date compared to 1.9% in the prior year’s quarter and 2.2% year to date. Third party sales, where reimbursement is received from managed care organizations as well as government and private insurance, were 95.4% of prescription sales for the quarter and the first nine months this year compared to 95.5% and 95.2% in the prior year. The total number of prescriptions filled for the third quarter was approximately 168 million compared to 158 million for the same period last year. Prescriptions adjusted to 30 day equivalents were 187 million in the third quarter verses 173 last year.

Front-end sales increased 7.4% for the current quarter and 6.7% for the first nine months and were 34.4% and 35.1% of total sales, respectively. In comparison, prior year front end sales increased 11.1% and 9.9% and comprised 34.5% and 35.3% of total sales. The overall increase is due to the addition of new stores and an increase in sales dollars related to consumables and household items. Offsetting the increase were decreases in sales dollars from seasonal items, photo and personal care. These factors contributed to comparable front-end sales increasing 0.9% in the current quarter and decreasing 0.2% year to date compared to increases of 4.6% and 4.4% last year.

Gross margin as a percent of sales was 27.5% in the current quarter and 27.9% for the first nine months compared to 28.3% and 28.4% last year. Overall margins were negatively impacted by lower front-end margins due to product mix, non-retail businesses, which have lower margins and are becoming a greater part of the total business, restructuring and restructuring related costs and a higher provision for LIFO. These items were partially offset by an improvement in retail pharmacy margins, which were positively influenced by generic drug sales, but to a lesser extent negatively influenced by the growth in third party pharmacy sales and lower market driven reimbursements.

We use the LIFO method of inventory valuation, which can only be determined annually when inflation rates and inventory levels are finalized; therefore, LIFO inventory costs for the interim financial statements are estimated. Cost of sales included a LIFO provision of $32 million and $124 million for the quarter and nine month period ended May 31, 2009 versus $16 million and $74 million a year ago. This quarter our estimated annual inflation rate was reduced to 2.0% from our estimate of 2.25% at February 28, 2009, primarily due to lower than projected prescription drug inflation. Last year, during the third quarter the estimated annual inflation rate was reduced to 1.25% from 1.5%, due to lower than projected non-prescription drug inflation.

Gross profit increased 5.0% in the quarter and 5.2% year to date versus 9.5% and 9.7% increases in the same periods last year. The change from the prior year is primarily due to lower sales growth and lower gross margins.

Selling, general and administrative expenses as a percentage of sales were 22.3% for the current quarter and 22.6% for the first nine months compared to 22.2% and 22.3% a year ago. As a percentage of sales, the current quarter and nine month period increases were due to higher restructuring and restructuring related expenses and occupancy, partially offset by lower store level salaries and savings related to our restructuring activities.

Selling, general and administrative expenses increased 8.4% in the third quarter and 8.5% for the nine month period ended May 31, 2009 compared to 10.2% and 10.5% a year ago. Restructuring and restructuring related expenses accounted for 1.0% of the increase in the current quarter and 1.3% of the increase for the nine month period. Partially offsetting restructuring and restructuring related expenses was a reduction in store level salaries for the current quarter and year to date. Store level salaries increased at a lower rate of growth than sales, contrary to the prior year where the rate of growth was higher than sales.

Interest was a net expense of $25 million in the quarter and $60 million year to date, compared to $2 million and $4 million in the prior quarter and year to date, respectively. The increase in interest expense is primarily attributed to the issuance of long-term debt. The current year’s interest expense is net of $3 million in the quarter and $12 million year to date, which was capitalized to construction projects versus $4 million in the quarter and $16 million year to date capitalized last year.

The effective tax rate was 36.4% for the quarter and 36.8% for the first nine months compared to 37.3% and 37.1% a year ago. The decrease in rate is attributed to additional permanent tax benefits in the current year.

CRITICAL ACCOUNTING POLICIES

The consolidated condensed financial statements are prepared in accordance with accounting principles generally accepted in the United States of America and include amounts based on management's prudent judgments and estimates. Actual results may differ from these estimates. Management believes that any reasonable deviation from those judgments and estimates would not have a material impact on our consolidated financial position or results of operations. To the extent that the estimates used differ from actual results, however, adjustments to the statement of earnings and corresponding balance sheet accounts would be necessary. These adjustments would be made in future statements. For a complete discussion of all our significant accounting policies please see our 2008 annual report on Form 10-K. Some of the more significant estimates include goodwill and other intangible asset impairment, allowance for doubtful accounts, vendor allowances, liability for closed locations, liability for insurance claims, cost of sales, and income taxes. We use the following methods to determine our estimates:

Goodwill and other intangible asset impairment -
	Goodwill and other indefinite-lived intangible assets are not amortized, but are evaluated for impairment annually or whenever events or changes in circumstances indicate that the value of a certain asset may be impaired. The process of evaluating goodwill for impairment involves the determination of fair value. Inherent in such fair value determinations are certain judgments and estimates, including the interpretation of economic indicators and market valuations and assumptions about our business plans. We have not made any material changes to the method of evaluating goodwill and intangible asset impairments during the last three years. Based on current knowledge, we do not believe there is a reasonable likelihood that there will be a material change in the estimate or assumptions used to determine impairment.
Allowance for doubtful accounts -
	The provision for bad debt is based on both specific receivables and historic write-off percentages. We have not made any material changes to the method of estimating our allowance for doubtful accounts during the last three years. Based on current knowledge, we do not believe there is a reasonable likelihood that there will be a material change in the estimate or assumptions used to determine the allowance.
Vendor allowances -
	Vendor allowances are principally received as a result of purchase levels, sales or promotion of vendors' products. Allowances are generally recorded as a reduction of inventory and are recognized as a reduction of cost of sales when the related merchandise is sold. Those allowances received for promoting vendors' products are offset against advertising expense and result in a reduction of selling, general and administrative expenses to the extent of advertising incurred, with the excess treated as a reduction of inventory costs. We have not made any material changes to the method of estimating our vendor allowances during the last three years. Based on current knowledge, we do not believe there is a reasonable likelihood that there will be a material change in the estimate or assumptions used to determine vendor allowances.
Liability for closed locations -
	The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. We have not made any material changes to the method of estimating our liability for closed locations during the last three years. Based on current knowledge, we do not believe there is a reasonable likelihood that there will be a material change in the estimate or assumptions used to determine the liability.
Liability for insurance claims -
	The liability for insurance claims is recorded to an actuarially determined estimate for claims incurred and is not discounted. The provisions are estimated in part by considering historical claims experience, demographic factors and other actuarial assumptions. We have not made any material changes to the method of estimating our liability for insurance claims during the last three years. Based on current knowledge, we do not believe there is a reasonable likelihood that there will be a material change in the estimate or assumptions used to determine the liability.
Cost of sales -
	Drugstore cost of sales is derived based on point-of-sale scanning information with an estimate for shrinkage and adjusted based on periodic inventories. Inventories are valued at the lower of cost or market determined by the LIFO method. We have not made any material changes to the method of estimating cost of sales during the last three years. Based on current knowledge, we do not believe there is a reasonable likelihood that there will be a material change in the estimate or assumptions used to determine cost of sales. Cost of sales will continue to be impacted by our restructuring initiatives which include inventory rationalization and the subsequent write-down of inventory to the lower of cost or market.
Income Taxes -
	We are subject to routine income tax audits that occur periodically in the normal course of business. U.S. federal, state and local and foreign tax authorities raise questions regarding our tax filing positions, including the timing and amount of deductions and the allocation of income among various tax jurisdictions. In evaluating the tax benefits associated with our various tax filing positions, we record a tax benefit for uncertain tax positions using the highest cumulative tax benefit that is more likely than not to be realized. Adjustments are made to our liability for unrecognized tax benefits in the period in which we determine the issue is effectively settled with the tax authorities, the statute of limitations expires for the return containing the tax position or when more information becomes available. Our liability for unrecognized tax benefits, including accrued penalties and interest, is included in other long-term liabilities on our consolidated balance sheets and in income tax expense in our consolidated statements of earnings. In determining our provision for income taxes, we use an annual effective income tax rate based on full year income, permanent differences between book and tax income, and statutory income tax rates. The effective income tax rate also reflects our assessment of the ultimate outcome of tax audits. Discrete events such as audit settlements or changes in tax laws are recognized in the period in which they occur. Based on current knowledge, we do not believe there is a reasonable likelihood that there will be a material change in the estimate or assumptions used to determine income taxes.

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents were $2,300 million at May 31, 2009, compared to $472 million at May 31, 2008. Short-term investment objectives are to minimize risk, maintain liquidity and maximize after-tax yields. To attain these objectives, investment limits are placed on the amount, type and issuer of securities. Investments are principally in U.S. Treasury market funds and Treasury Bills.

Net cash provided by operating activities for the nine months ending May 31, 2009 improved $768 million to $3,259 million compared to $2,491 million a year ago. The increase is primarily attributable to working capital improvements. For the nine months ended May 31, 2009 we generated $602 million in cash flow from working capital improvements, primarily through better inventory management. Working capital improvements were partially offset by lower net earnings. Last year, working capital improvements generated $114 million in cash flow. Cash provided by operations is the principal source of funds for expansion, acquisitions, remodeling programs, dividends to shareholders and stock repurchases. In fiscal 2009, we supplemented cash provided by operations with long-term debt.

Net cash used for investing activities was $1,936 million versus $2,154 million last year. Using the proceeds from our issuance of long-term debt we invested $650 million in short-term Treasury Bills of which $550 million was redeemed in the third quarter. Additions to property and equipment were $1,534 million compared to $1,653 million last year. During the first nine months we added a total of 525 locations (427 net) compared to 797 last year (730 net). There were 140 owned locations added during the first nine months and 53 under construction at May 31, 2009 versus 166 owned locations added and 67 under construction last year.

	Drugstores			Worksites			Home Care			Specialty Pharmacy			Mail Service		Total
August 31, 2008		6,443			364			115			10			2		6,934
New/Relocated		407			28			4			4			-		443
Acquired		64			2			11			5			-		82
Closed/Replaced		(57	)		(21	)		(18	)		(2	)		-		(98	)
May 31, 2009		6,857			373			112			17			2		7,361

Business acquisitions this year were $348 million versus $527 million in the prior year. Business acquisitions in the current year include the acquisition of 34 Drug Fair locations, McKesson Corporation’s specialty pharmacy, a business within McKesson’s Specialty division and IVPCARE, a specialty pharmacy focused on reproductive health and selected other assets (primarily prescription files).

Capital expenditures throughout fiscal 2009 are expected to be $1.9 billion, excluding business acquisitions. We expect to open approximately 540 new drugstores in fiscal 2009, with a net increase of approximately 475 drugstores and anticipate having a total of more than 7,000 drugstores in 2010. We intend to achieve new drugstore organic growth between 4.0 percent and 4.5 percent in fiscal 2010 and between 2.5 percent and 3.0 percent in 2011. In the first nine months, we added a total of 525 locations, of which 407 were new or relocated drugstores, with a net gain of 414 drugstores after relocations and closings. We are continuing to relocate stores to more convenient freestanding locations. In addition to new stores, expenditures are planned for distribution centers and technology. Capital expenditures for fiscal 2010 are expected to be approximately $1.6 billion, excluding business acquisitions and prescription file purchases.

Net cash provided by financing activities was $534 million compared to a net cash use of $120 million last year. On January 13, 2009, we issued $1,000 million of 5.25% notes due in 2019. The notes were issued at a discount. The net proceeds after deducting the discount, underwriting fees and issuance costs were $987 million. The proceeds were used to pay down short-term borrowings with the excess used to purchase short term investments in Treasury Bills. Short-term borrowings paid during the current fiscal year were $70 million compared to proceeds of $263 million a year ago. Shares totaling $140 million were purchased to support the needs of the employee stock plans during the current period as compared to $220 million a year ago. On January 10, 2007, a stock repurchase program (“2007 repurchase program”) of up to $1,000 million was announced, to be executed over four years. No repurchases were made under the 2007 repurchase program during the current or prior year. We plan to continuously evaluate executing any stock repurchases under the 2007 repurchase program throughout the year. We will continue to repurchase shares to support the needs of the employee stock and option plans. In the first nine months of the current year, we had proceeds related to employee stock plans of $106 million versus $161 million for the same period last year. Cash dividends paid were $334 million during the first nine months versus $283 million for the same period a year ago.

We had no commercial paper outstanding at May 31, 2009. In connection with our commercial paper program, we maintain two unsecured backup syndicated lines of credit that total $1,200 million. The first $600 million facility expires on August 10, 2009, the second on August 12, 2012. Our ability to access these facilities is subject to our compliance with the terms and conditions of the credit facilities, including financial covenants. The covenants require us to maintain certain financial ratios related to minimum net worth and priority debt, along with limitations on the sale of assets and purchases of investments. As of May 31, 2009 we were in compliance with all such covenants. The company pays a facility fee to the financing bank to keep this line of credit facility active. While we are still able to access these lines of credit, as of May 31, 2009, there were no borrowings outstanding against these credit facilities. We do not expect any borrowings under these facilities, together with our outstanding commercial paper, to exceed $1,200 million.

Our current credit ratings are as follows:

Rating Agency	Long-Term Debt Rating	Outlook	Commercial Paper Rating	Outlook
Moody's	A2	Stable	P-1	Stable
Standard & Poor's	A+	Negative	A-1	Negative

In assessing our credit strength, both Moody's and Standard & Poor's consider our business model, capital structure, financial policies and financial statements. Our credit ratings impact our future borrowing costs, access to capital markets and operating lease costs.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

The following table lists our contractual obligations and commitments as of May 31, 2009:

	Payments Due by Period (In millions)
	Total		Less than 1 Year		1-3 Years		3-5 Years		Over 5 Years
Operating leases (1)	$	34,557	$	1,952	$	4,083	$	3,967	$	24,555
Purchase obligations (2):
Open inventory purchase orders		1,213		1,213		-		-		-
Real estate development		760		737		23		-		-
Other corporate obligations		474		239		153		47		35
Long-term debt*		2,350		7		4		1,304		1,035
Interest payment on long-term debt		811		114		232		200		265
Insurance*		491		162		115		82		132
Retiree health*		285		9		23		29		224
Closed location obligations*		84		19		25		14		26
Capital lease obligations *(1)		40		2		4		3		31
Other long-term liabilities reflected on the balance sheet*(3)		665		46		113		115		391
Total	$	41,730	$	4,500	$	4,775	$	5,761	$	26,694

* Recorded on balance sheet.

(1)	Amounts for operating leases and capital leases do not include certain operating expenses under the leases such as common area maintenance, insurance and real estate taxes. These expenses for the company's most recent fiscal year were $298 million.
(2)	The purchase obligations include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including open purchase orders.
(3)	Includes $58 million ($18 million due in 1-3 years, $27 million due in 3-5 years and $13 million due in over 5 years) of unrecognized tax benefits recorded under FIN No. 48, which we adopted in fiscal year 2008.

OFF-BALANCE SHEET ARRANGEMENTS

Letters of credit are issued to support purchase obligations and commitments (as reflected on the Contractual Obligations and Commitments table) as follows (In millions):

Insurance	$	265
Inventory obligations		62
Real estate development		15
Other		8
Total	$	350

We have no other off-balance sheet arrangements other than those disclosed on the Contractual Obligations and Commitments table and a credit agreement guaranty on behalf of SureScripts-RxHub, LLC. This agreement is described more fully in Note 8 in the Notes to Consolidated Condensed Financial Statements.

Both on-balance sheet and off-balance sheet financing are considered when targeting debt to equity ratios to balance the interests of equity and debt (including real estate) investors. This balance allows us to lower our cost of capital while maintaining a prudent level of financial risk.

RECENT ACCOUNTING PRONOUNCEMENTS

In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements . This statement, and the related pronouncements, defines and provides guidance when applying fair value measurements to accounting pronouncements that require or permit such measurements. We adopted the provisions of SFAS 157, Fair Value Measurements for financial assets and liabilities beginning in the first quarter of fiscal 2009. FASB Staff Position No. 157-2 deferred the effective date of nonfinancial assets and liabilities until fiscal year 2010. We do not expect to have a material impact in 2010 when we apply the statement to our nonfinancial assets and liabilities.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interest in Consolidated Financial Statements – an amendment of Accounting Research Bulletin No. 51 . The objective of this statement is to improve the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements by establishing accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. The statement significantly changes the accounting for transactions with minority interest holders. This statement, which will be effective for the first quarter of fiscal 2010, is not expected to have a material impact on our consolidated financial position or results of operations.

In December 2007, the FASB issued SFAS No. 141(R), Business Combinations . This statement establishes principles and requirements for how the acquirer recognizes and measures identifiable assets acquired, liabilities assumed and any noncontrolling interest in a business combination. In addition the statement provides a revised definition of a business, shifts from the purchase method to the acquisition method, expenses acquisition-related transaction costs, recognizes contingent consideration and contingent assets and liabilities at fair value, and capitalizes acquired in-process research and development. This statement, which will be effective for the first quarter of fiscal 2010, will be applied prospectively to business combinations. In addition, changes in an acquired entity’s deferred tax assets and uncertain tax positions after the measurement period will impact income tax expense.

In June of 2009, the FASB approved its Accounting Standards Codification, or Codification, as the single source of authoritative United States accounting and reporting standards applicable for all non-governmental entities, with the exception of the SEC and its staff. The Codification, which changes the referencing of financial standards, is effective for interim or annual financial periods ending after September 15, 2009. Therefore, in the first quarter of fiscal 2010, all references made to US GAAP will use the new Codification numbering system prescribed by the FASB. As the Codification is not intended to change or alter existing US GAAP, it is not expected to have any impact on our consolidated financial position or results of operations.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information in this quarterly report on Form 10-Q, as well as in other public filings, the company website, press releases and oral statements made by our representatives, is forward-looking information based on current expectations and plans that involve risks and uncertainties. Forward-looking information includes statements concerning pharmacy sales trends, prescription margins, number and location of new store openings, outcomes of litigation, the level of capital expenditures, and demographic trends. Forward looking information includes statements with words such as "expects," "estimates," "intends," "believes," "plans," "anticipates" or similar language. For such statements, we claim the protection of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements involve risks and uncertainties, known or unknown to the company, that could cause results to differ materially from management expectations as projected in such forward-looking statements. These risk and uncertainties are discussed in Item 1A of the company’s annual report on Form 10-K for the period ended August 31, 2008 as well as other documents filed with the Securities and Exchange Commission. Unless otherwise required by applicable securities laws, the company assumes no obligation to update its forward-looking statements to reflect subsequent events or circumstances.

Item 3. QUALITATIVE AND QUANTITATIVE DISCLOSURE ABOUT MARKET RISK

Management does not believe that there is any material market risk exposure with respect to derivative or other financial instruments that would require disclosure under this item.

Item 4. CONTROLS AND PROCEDURES

Based on their evaluation as of May 31, 2009, pursuant to Exchange Act Rule 13a-15(b), the company's management, including its Chief Executive Officer and Chief Financial Officer, has concluded that the company's disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)) are effective.

In connection with the evaluation pursuant to Exchange Act Rule 13a-15(d) of the company's internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) by the company's management, including its Chief Executive Officer and Chief Financial Officer, no changes during the quarter ended May 31, 2009 were identified that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

The company is involved in legal proceedings, and is subject to investigations, inspections, audits, inquiries and similar actions by governmental authorities, incidental to the normal course of the company’s business.

On April 16, 2008, the Plumbers and Steamfitters Local No. 7 Pension Fund filed a putative class action suit against the company and its former Chief Executive Officer and Chief Operating Officer in the United States District Court for the Northern District of Illinois. The suit was filed on behalf of purchasers of company common stock during the period between June 25, 2007, and November 29, 2007. The complaint which was amended on October 16, 2008 charges the company and its former Chief Executive Officer and Chief Operating Officer with violations of Section 10(b) of the Securities Exchange Act of 1934, claiming that the company misled investors by failing to disclose declining rates of growth in generic drug sales and a contract dispute with a pharmacy benefits manager that allegedly had a negative impact on earnings. The company and the officers named in the suit believe the allegations are without merit, and intend to defend against them vigorously.

Although the outcome of this litigation and other legal proceedings and investigations to which the company is subject cannot be forecast with certainty, management believes the final disposition of these matters will not have a material adverse effect on the company's consolidated financial position or results of operations.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(c)	The following table provides information about purchases by the company during the quarter ended May 31, 2009 of equity securities that are registered by the company pursuant to Section 12 of the Exchange Act:

Issuer Purchases of Equity Securities
Period	Total Number of Shares Purchased (1)	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (2)
3/1/2009 - 3/31/2009	-	-	-	$655,123,821
4/1/2009 - 4/30/2009	-	-	-	$655,123,821
5/1/2009 - 5/31/2009	-	-	-	$655,123,821
Total	-	-	-	$655,123,821

(1)	The company did not purchase any shares of its common stock in open-market transactions to satisfy the requirements of the company's employee stock purchase and option plans, as well as the company's Nonemployee Director Stock Plan.
(2)	On January 10, 2007, the Board of Directors approved a stock repurchase program ("2007 repurchase program"), pursuant to which up to $1,000 million of the company's common stock may be purchased prior to the expiration date of the program on January 20, 2011. This program was announced in the company's report on Form 8-K, which was filed on January 11, 2007. The total remaining authorization under the repurchase program is $655,123,821 as of May 31, 2009.

Item 6. EXHIBITS

(a)

Exhibits

	3.1	Articles of Incorporation of Walgreen Co., as amended, filed with the Securities and Exchange Commission as Exhibit 3(a) to Walgreen Co.’s Quarterly Report on Form 10-Q for the quarter ended February 28, 1999 (File No. 1-00604), and incorporated by reference herein.

	3.2	Amended and Restated By-Laws of Walgreen Co., as amended effective as of September 1, 2008, filed with the Securities and Exchange Commission on September 5, 2008 as Exhibit 3.1 to Walgreen Co.’s Current Report on Form 8-K (File No. 1-00604), and incorporated by reference herein.

	10.1	Separation and Release Agreement effective as of March 31, 2009 between Walgreen Co. and William M. Rudolphsen.

	12	Computation of Ratio of Earnings to Fixed Charges.

	31.1	Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	31.2	Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	32.1	Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.

	32.2	Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	WALGREEN CO.
	(Registrant)

Dated: 6/25/09	/s/ W.D. Miquelon
	W.D. Miquelon
	Senior Vice President
	(Chief Financial Officer)

Dated: 6/25/09	/s/ M.M. Scholz
	M.M. Scholz
	Controller
	(Chief Accounting Officer)

Walgreen Co. Rewiring for Growth Salary Continuation Plan

Salary Grade 18 and Above Voluntary Group

Separation and Release Agreement

This Separation and Release Agreement (“Agreement”) is entered into between the undersigned employee (“Employee”) and Walgreen Co., its parents, subsidiaries, affiliated companies, predecessors, successors and assigns ("Walgreens" or the "Company"), who agree as follows:

1. Termination Date. The parties agree that Employee resigns and Employee’s employment with the Company is voluntarily terminated effective March 31, 2009, or such other date as designated by the Company and agreed to by Employee prior to execution of this Agreement.

2. General Waiver & Release. Employee waives and releases any and all claims, known or unknown, arising on or before the date Employee signs this Agreement, that Employee has or might have against the Company, its parents, subsidiaries, affiliated companies, predecessors, successors, and assigns, as well as all of its and their past and present officers, directors, managers, employees, attorneys, and agents (collectively “Released Parties”), subject only to the exceptions identified in paragraph 3 below. These waived and released claims include but are not limited to: (i) claims that in any way relate to Employee’s employment, separation from employment and other dealings of any kind with any Released Party or Parties; (ii) claims of unlawful discrimination, harassment, retaliation or other alleged violations arising under federal, state, local or others laws and regulations, including but not limited to claims arising under the federal Age Discrimination in Employment Act (ADEA); Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1866; the Employee Retirement Income Security Act (ERISA); the Americans with Disabilities Act (ADA); the Fair Labor Standards Act (FLSA); the Worker Adjustment and Retraining Notification Act (WARN); and the Family and Medical Leave Act (FMLA); (iii) claims of wrongful discharge, emotional distress, defamation, misrepresentation, fraud, detrimental reliance, breach of alleged contractual obligations, promissory estoppel, negligence, assault and battery, and violation of public policy; and (iv) claims for monetary damages, other personal recovery or relief, costs, expenses, and attorneys’ fees of any kind.

3. Claims Not Waived and Released. The only claims not waived and not released by Employee under paragraph 2 are (i) claims arising after the date that Employee signs this Agreement; (ii) any claim that as a matter of law cannot be waived; and (iii) claims for benefits that are specifically described and provided for in this Agreement.

4. No Disparagement. Employee will not make derogatory statements, either written or oral, or otherwise disparage any Released Party or Walgreens products or services, except as may be required to be permitted by law. Nor shall Employee direct, arrange or encourage others to make any such derogatory or disparaging statements on Employee's behalf.

5. Return of Company Property. Employee agrees that, no later than his/her Termination Date, Employee will have returned all Company property, and no Company property has been retained by the Employee, regardless of the form in which it was acquired or held by Employee.

6. Confidential Business Information. Employee agrees not to use or disclose any Confidential Information, as defined below, to any person or entity other than the Company, either before or after his/her Termination Date, without the Company's prior written consent. Confidential Information means information not generally known by the public about processes, systems, products or services, including proposed products or services, business information, pricing, sales, promotions, financial performance, know-how, or trade secrets of the Company.

7. Non-Admissions. Nothing in this Agreement constitutes or shall be portrayed or regarded as an admission of any wrongdoing, fault, violation, liability, or unlawful activity by the Company or any Released Party.

8. Cooperation. Subject to paragraph 3 above, upon reasonable notice, Employee agrees at all times to fully and completely cooperate with the Company and its agents and representatives, without additional compensation, during and in connection with all litigation, potential litigation, and internal or external investigations in which the Company is involved or may become involved, subject to reimbursement of reasonable travel expenses if travel is requested and approved in advance by Walgreens.

9. Investigations and Related Proceedings. Nothing in this Agreement shall affect or interfere with Employee’s right to participate, cooperate, initiate or assist in an investigation or proceeding conducted within the Company or by any government agency, oversight board, commission or other regulatory or investigative body.

10. Reemployment Restrictions. Employee acknowledges that he/she will not be eligible for reemployment with the Company once he/she has terminated employment.

11. Non-Competition and Non-Solicitation. Employee has executed a Non-Competition, Non-Solicitation and Confidentiality Agreement in connection with his or her award of Restricted Stock Units for fiscal year 2009 (the “RSU Non-Compete”), and Employee hereby acknowledges and reaffirms his/her continuing obligations under the RSU Non-Compete in connection with the execution of this Agreement, subject to the following modifications:

(a) The non-competition restrictions set forth in Paragraph 2(d) of the RSU Non-Compete shall apply through Employee’s last day worked and for a period thereafter equal to the number of weeks for which Employee receives salary continuation benefits under the Walgreen Co. Rewiring for Growth Salary Continuation Plan (the “Plan”) and the Supplement for Employees Grades 12 and Higher (the “Supplement”), regardless of the timing of payment of such benefits; and

(b) The restrictions set forth in Paragraph 2(a-c) of the RSU Non-Compete shall apply through Employee’s last day worked and for the two-year period immediately following such last day worked.

12. Salary Continuation Plan Benefits. Walgreens agrees to pay Employee benefits under the Plan and Supplement, provided that Employee is eligible for benefits under the terms of the Plan and Supplement and executes this Agreement. Walgreens also agrees to pay Employee additional compensation and benefits. Such Plan, Supplement and additional benefits are described in the attached Exhibit A. To the extent that Employee is eligible under the Plan and/or Supplement for a retirement bridge under one or more Company benefit plans or programs, Employee’s execution of this Agreement will constitute his/her official consent to any amendments to any applicable award agreements or other plan documentation, as may be needed to carry out the terms of the retirement bridge. Employee will receive the same notice of changes to plans or stock options as other retired Walgreens employees.

13. Unemployment Compensation. Employee acknowledges that he/she is voluntarily resigning from employment with the Company and that the Company reserves the right to dispute any claim for unemployment compensation benefits, to the extent permitted by law.

14. Consequences of Breach by Employee . Plan benefits are conditioned on compliance with all Employee commitments set forth in this Agreement. In the event of any breach of this Agreement by Employee, the Company shall be entitled to discontinue and recover all Plan benefits otherwise payable to Employee, except for $200 to be retained by Employee as consideration for enforcement of non-breached provisions of the Agreement. In addition, Employee acknowledges that Section 11 of this Agreement is necessary to enable the Company to maintain its competitive position and any actual or threatened breach of this covenant will result in irreparable and continuing damage to the Company for which there will be no adequate remedy at law. In the event of any actual or threatened breach of these covenants, the Company shall be entitled to injunctive relief, including the right to a temporary restraining order, and other relief, including damages, as may be proper along with the Company’s attorney’s fees and court costs. The foregoing stipulated damages and remedies of the Company are in addition to, and not to the exclusion of, any other damages the Company may be able to prove.

15. 409A Compliance . Employee acknowledges that in order to avoid adverse tax consequences to Employee under Section 409A of the Internal Revenue Code, certain benefits under the Plan and Supplement may need to be paid on a delayed basis as soon as administratively possible following the six-month anniversary of the Termination Date.

16. New Section: The Employee and Company agree that material changes have been made to the benefits originally presented to the Employee by (a) revising Section 12 and adding Exhibit A, and (b) by adding Section 15. The parties agree that such modifications shall not restart the running of the 45-day period described in paragraph 18(f) below.

17. Severability . In the event that any portion of this Agreement is held by a court of competent jurisdiction to be invalid or unenforceable, the invalid or unenforceable portion shall be construed or modified in a manner that gives force and effect, to the fullest extent possible, to all other portions and provisions of this Agreement. If any invalid or unenforceable portion of any provision in this Agreement cannot be construed or modified to render it valid and enforceable, that portion shall be construed as narrowly as possible and shall be severed from the remainder of this Agreement, and the remainder of this Agreement (including the remainder of the section, paragraph, subparagraph or sentence containing any invalid or unenforceable words) shall remain in effect to the fullest extent possible.

18. OWBPA Provisions – Additional Understandings. In compliance with the Older Workers Benefit Protection Act (“OWBPA”), the Company and Employee agree to the following:

(a)	Understandability . This Agreement is written in a manner calculated to be understood by the Employee, and Employee understands all terms of this Agreement;

(b)	Age Discrimination (ADEA) Waiver . This Agreement includes a waiver and release of claims under the Age Discrimination in Employment Act (ADEA) as described in paragraph 2 above;

(c)	No Future Waiver . This Agreement only waives and releases rights arising prior to the date Employee signs this Agreement;

(d)	Valid Consideration . In exchange for Employee's release and waiver as part of this Agreement, Employee acknowledges that he/she is receiving benefits as described in the Plan and Supplement that exceed those to which Employee is entitled apart from this Agreement;

(e)	Employee Advised to Consult with an Attorney . By this Agreement, the Company advises Employee to consult with an attorney before signing this Agreement;

(f)	Period to Consider this Agreement . Employee has been given a period of 45 calendar days in which to consider this Agreement, and to decide whether s/he wishes to sign it;

(g)	Information Provided . Employee has received, together with this Agreement, a listing of job titles and ages of Employees eligible or not eligible for Plan benefits pursuant to the Rewiring for Growth Project;

(h)

Period to Revoke Agreement . After Employee signs this Agreement, Employee has 7 calendar days in which Employee can change his or her mind and revoke this Agreement. Walgreens and Employee agree that, to revoke this Agreement, Employee must notify Walgreens in writing that Employee is revoking this Agreement. Any such notice of revocation must be received by Deidra Byrd, Divisional Vice President, Employee Relations, 102 Wilmot Road, Deerfield, Illinois 60015, fax no. (847)315-4699, deidra.byrd@walgreens.com, within the 7-day period; and

(i)	Effective Date . This Agreement shall not become effective or enforceable until the 7-day revocation period described above has expired with no revocation by Employee.

19. Agreement Not Signed Before Termination Date . Employee represents and agrees that he/she has waited until his Termination Date before signing this Agreement.

20. Governing Law. The laws of the State of Illinois shall govern the validity, performance, enforcement, interpretation and any other aspect of this Agreement, notwithstanding any state’s choice of law provisions to the contrary.

21. Complete Agreement. This Agreement constitutes the parties’ entire agreement and cancels, supersedes, and replaces any and all prior proposals, understandings, and agreements (written, oral or implied) regarding all matters addressed herein, except Employee shall continue to be bound by all obligations set forth in any prior agreements, undertakings, waivers and assignments involving confidential information, inventions, non-competition, non-solicitation, non-inducement, patents, copyrights, trademarks and other intellectual property, and compliance with laws and policies. The terms of this Agreement may not be altered or modified except by written agreement of the Employee and the Company. In connection with this Agreement’s acceptance and execution, neither Employee nor the Company is relying on any representation or promise that is not expressly stated in this Agreement.

The Employee has read everything in this Separation and Release Agreement, understands it, and signs this Agreement voluntarily and intending to be bound by it.

This Agreement shall not be signed or returned before the Employee’s Termination Date .

Dated: 4 /2/09 s/ William M. Rudolphsen

Employee Signature

William M. Rudolphsen

Employee Name (Print)

Dated: 4 /6 /09 s/ Kris Dimitriou

On behalf of the Company

EXHIBIT A

Separation Benefits for Bill Rudolphsen

This is a summary of your separation benefits. All of the detailed terms and conditions are set forth in the Plan and Supplement and as applicable in the underlying compensation and benefit plans and programs.

Termination Date (PTD)

3/31/09

Vacation

Current year plus banked

Severance and Fiscal 09 Bonus

$1,137,430

Form of vacation/severance

Lump-sum following PTD, subject to six-month delay of a /bonus paymentsportion to comply with tax law requirements (409A)*

Deferred Compensation

Enhanced lump-sum with gross-up per Voluntary Program (subject to six-month delay under 409A)*

Stock Option Exercise Periods

Retirement provision under stock option agreements apply (in most cases 60 months from PTD, or 10-year expiration date, if earlier)

RPSP Restricted Shares/Cash

Accelerated vesting and paid out at PTD (subject to six-month delay of cash payment under 409A)*

Fiscal 2009 Restricted Stock Units

Pro-rated vesting through PTD and shares distributed after PTD (subject to six-month delay under 409A)*

Fiscal 2009 Performance Shares

Pro-rated through PTD and paid out in October 2011 based on actual company performance

Profit Sharing/Restoration

Deductions and match apply to vacation but not severance

Retiree Medical

Eligible – begins after PTD**

SVP Retirement Benefits

Co. physical and United preferred status to age 70**

Other Benefits

End as of PTD

Outplacement

Up to 12 months

* See separate letter covering timing of payment to ensure 409A compliance.

** Subject to any future program/policy changes generally applicable to retirees.

Exhibit 12

WALGREEN CO. AND SUBSIDIARIES

COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

	Nine Months Ended May 31,
	2009			2008
Income before income taxes and minority interest	$	2,485		$	2,726
Add:
Minority interest		-			-
Fixed charges		733			616
Less: Capitalized interest		(12	)		(16	)
Earnings as defined	$	3,206		$	3,326

Interest expense, net of capitalized interest	$	60		$	4
Capitalized interest		12			16
Portions of rentals representative of the interest factor		661			596
Fixed charges as defined	$	733		$	616

Ratio of earnings to fixed charges		4.37			5.40

EXHIBIT 31.1

CERTIFICATION

I, Greg D. Wasson, Chief Executive Officer, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Walgreen Co.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


/s/		Greg D. Wasson	Chief Executive Officer	Date: June 25, 2009
		Greg D. Wasson

EXHIBIT 31.2

CERTIFICATION

I, Wade D. Miquelon, Chief Financial Officer, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Walgreen Co.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


/s/		Wade D. Miquelon	Chief Financial Officer	Date: June 25, 2009
		Wade D. Miquelon

Exhibit 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Walgreen Co., an Illinois corporation (the "Company"), on Form 10-Q for the quarter ended May 31, 2009 as filed with the Securities and Exchange Commission (the "Report"), I, Greg D. Wasson, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Greg D. Wasson

Greg D. Wasson

Chief Executive Officer

Dated: June 25, 2009

A signed original of this written statement required by Section 906 has been provided to Walgreen Co. and will be retained by Walgreen Co. and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Walgreen Co., an Illinois corporation (the "Company"), on Form 10-Q for the quarter ended May 31, 2009 as filed with the Securities and Exchange Commission (the "Report"), I, Wade D. Miquelon, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Wade D. Miquelon

Wade D. Miquelon

Chief Financial Officer

Dated: June 25, 2009